Arca Biopharma Inc., of Westminster, Colo., said the 200th patient has been randomized into Genetic-AF, an adaptive, seamless design phase IIb/III trial evaluating Gencaro (bucindolol hydrochloride) as potentially the first genetically targeted treatment for atrial fibrillation (AF).